Doxorubicin Induced Nephrotoxicity: Protective Effect of Nicotinamide by Ayla, Sule et al.
Hindawi Publishing Corporation
International Journal of Cell Biology
Volume 2011, Article ID 390238, 9 pages
doi:10.1155/2011/390238
Research Article
DoxorubicinInducedNephrotoxicity:
Protective Effectof Nicotinamide
SuleAyla,1 IsmailSeckin,2 Gamze Tanriverdi,2 MujganCengiz,3 Mediha Eser,3
B. C. Soner,4 andGulperiOktem5
1Suleymaniye Woman Health Hospital, 34122 Istanbul, Turkey
2Department of Histology and Embryology, Cerrahpasa School of Medicine, Istanbul University, 34452 Istanbul, Turkey
3Department of Medical Biology, Cerrahpasa School of Medicine, Istanbul University, 34452 Istanbul, Turkey
4Department of Pharmacology, Meram School of Medicine, Selcuk University, 42080 Konya, Turkey
5Department of Histology and Embryology, Ege University School of Medicine, 35100 Izmir, Turkey
Correspondence should be addressed to Gulperi Oktem, gulperi.oktem@ege.edu.tr
Received 31 January 2011; Revised 25 April 2011; Accepted 16 May 2011
Academic Editor: Richard Gomer
Copyright © 2011 Sule Ayla et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction.Nephrotoxicityisoneoftheimportantsideeﬀectsofanthracyclineantibiotics.Theaimofthisstudywastoinvestigate
the eﬀects of nicotinamide (NAD), an antioxidant agent, against nephrotoxicity induced by doxorubicin (DXR). Methods.T h era t s
were divided into control, NAD alone, doxorubicin (20mg/kg, i.p.) and DXR plus NAD (200mg/kg, i.p.) groups. At the end of the
10th day, kidney tissues were removed for light microscopy and analysis. The level of tissues’ catalase (CAT), glutathione (GSH),
glutathione peroxidase (GPx), inducible nitric oxide (iNOS) and endothelial nitric oxide (eNOS) activities were determined.
Results. The activities of CAT, GPx, and GSH were decreased, and Po was increased in renal tissue of doxorubicin group compared
with other groups. The tissue of the doxorubicin group showed some histopathological changes such as glomerular vacuolization
and degeneration, adhesion to Bowman’s capsule and thickening and untidiness of tubular and glomerular capillary basement
membranes. Histopathological examination showed that NAD prevented partly DXR-induced tubular and glomerular damage.
Conclusions. Pretreatment with NAD protected renal tissues against DXR-induced nephrotoxicity. Preventive eﬀects of NAD on
these renal lesions may be via its antioxidant and anti-inﬂammatory action.
1.Introduction
Quinine-containing anthracycline antibiotic doxorubicin
(DXR) has been used for the treatment of cancer since
1969. In spite of its high antitumor eﬃcacy, DXR’s use in
chemotherapy has been largely limited due to its cardiac,
renal, pulmonary, testicular, and hematological toxicities [1,
2]. DXR causes an imbalance between free oxygen radicals
and antioxidants. The disturbance in oxidant-antioxidant
systems which has been demonstrated with lipid peroxida-
tion (LPO) and protein oxidation results with tissue injury
[3].AlthoughtheexactmechanismofDXR-inducednephro-
toxicity remains unknown, it is believed that the toxicity may
be mediated through free radical formation, iron-dependent
oxidative damage of biological macromolecules, membrane
LPO, and protein oxidation [4]. DXR-induced changes in
the kidneys of rats include increased glomerular capillary
permeability and tubular atrophy [5].
Nitric oxide (NO) is a free radical gas which acts as
a cytoprotective or a cytotoxic agent. NO is generated by
either endothelial nitric oxide synthase (eNOS) or inducible
nitric oxide synthase (iNOS) [6]. Possible role of DXR in
NOS metabolism occurs via direct or indirect stimulation
of NO production, and this might be a consequence of
increased free radical generation. Free radical production
and/or NO release induced by DXR is entirely responsible
for the DXR-induced toxicity [7]. Mitochondria has been
deﬁned as one of the targets in DXR-induced subcellular
damage in the tissue. In addition, it has been shown that
DXR could stimulate transmembranal arginine transport to
provide increased substrate and activate NOS mediated NO-
production [8].2 International Journal of Cell Biology
Nicotinamide (NAD), a derivative of Vitamin B3,h a s
been shown to exert a number of anti-inﬂammatory prop-
erties like iNOS inhibition suppression of both MHC
class II and intracellular adhesion molecule expression on
endothelial cells [9, 10]. It has been suggested that NAD has
an ability to inhibit poly(ADP-ribose) polymerase (PARP)
whichhasbeendeﬁnedasanuclearDNArepairenzyme[11].
NAD has been shown to have antioxidant activity. Besides
inhibiting protein oxidation and lipid peroxidation, it also
inhibits reactive oxygen species-induced apoptosis [12]. The
present study was therefore designed to investigate the eﬀects
of NAD on lipid peroxidation, antioxidant status, and iNOS
activity in DXR-induced nephrotoxicity in rats.
2.MaterialsandMethods
2.1. Animals and Experimental Protocol. Male Wistar-albino
rats weighing 250 ± 30g (mean-standard deviation) were
used in the experiments. A standard diet and tap water
were provided ad libitum. The experimental protocols were
approved by the Cerrahpasa Medical School Animal Ethical
Committee of Istanbul University. Control group was treated
intraperitonealy with 0.9%, NaCl for 10 days (n = 6); NAD
group was treated with i.p. NAD (Sigma Chemical Co., USA)
alone for 10 days (200mg/kgb.wt/day) (n = 8); DXR group
was treated with single i.p. injection of DXR (20mg/kg/b.wt)
(n = 8) [13]; DXR + NAD group received DXR and NAD
combinationtreatment(n = 8)inwhichNADtreatmentwas
begun 1 day before DXR treatment.
2.2. Sample Collection and Biochemical Assay. At the 10th
day of DXR treatment, the animals were anesthetized
with pentobarbital (I.E. ULUGAY Istanbul, Turkey) (i.p.
6.5mg/kg), the right kidney was rapidly excised and sec-
tionedverticallyintotwopiecesformicroscopicexamination
and biochemical analysis. The renal tissue was stored at
−70◦C until biochemical analyses. Kidneys were thawed
and homogenized (10%W/V) with 0.15 KCl at 4◦C then
centrifuged at 10,000g for 1.5h. The supernatant was used
as the source of experimental product. Glutathione (GSH)
assay was determined by the method of Beutler et al. [14]
with 5.5 dithio bis nitrobenzoic acid as product. The catalase
activity was performed by Aebi’s method [15]. Glutathione
peroxidase activity was measured by the method of Paglia
and Valentine [16]. Protein oxidation was determined
according to the technique which was reported by Levine
et al. [17]. Protein levels were measured by Lowry method.
All the measurements were done by schimadzu 1601 UV
spectrophotometer.
2.3. Light Microscopy. The kidneys were sectioned and ﬁxed
in 10% formalin, dehydrated and embedded in paraﬃn.
T i s s u e sw e r es e c t i o n e da t5 μm and stained with periodic
acid Schiﬀ (PAS). The histological slides of kidney were
evaluated for semiquantitative analysis without knowledge
of the treatment protocol, as described previously [18]. A
semiquantitative score was developed to evaluate the degree
of the damage. A minimum of 20 glomeruli (range 20 to
60) in each specimen was examined, and the severity of the
lesion was graded from 0 to 4+ according to the percentage
of glomerular involvement. Thus, a 1+ lesion represented an
involvement of 25% of the glomerulus, while a 4+ lesion
indicated that 100% of the glomerulus was involved. An
injury score was then obtained by multiplying the degree of
damage (0 to 4+) by the percentage of the glomeruli with the
same degree of injury, that is, increase in mesangial matrix
material or glomerulosclerosis. The extent of the injury for
each individual tissue specimen was then obtained by the
addition of these scores. For example, if 5 of 20 glomeruli
had a lesion of 1+ and 5 of 20 had a lesion of 3+, the ﬁnal
injury score for that specimen would be (1 × 5/20) + (3 ×
5/20) × 100 = 100. The injury score for individual tissue
specimens derived by each investigator varied from 11% in
the specimens with minimal changes (0 to 1+) up to 18% in
specimens with more severe and widespread (2 to 4+) injury.
The scores obtained by the two investigators were averaged
(Figure 1).
2.4. Electron Microscopy. The samples were dissected to
1mm 3 and ﬁxed by 4% glutaraldehyde which is prepared
by Soransen’s phosphate buﬀer pH: 7.4 for 1h. Samples
were washed with phosphate buﬀer for 1h and applied after
ﬁxation by Osmium tetroxide (OsO4)w h i c hi sp r e p a r e db y
Milloning’s buﬀer. The ﬁxed samples were dehydrated in
ethanol, embedded in Araldite, and cut into 500–700 ˚ A. The
cross-sections were then taken on copper grid and stained
with uranyl acetate and Reynold’s Leade Citrate. The coppers
were investigated with Jeol JEM 1011.
2.5. Tissue Processing and Immunohistochemistry. Tissue
pieces were ﬁxed in 4% paraformaldehyde (Sigma Chemical
Co., St. Louis, Mo, USA) for 24h at 4◦C and processed
for embedding in paraﬃn wax using routine protocols.
5μm thick coronal sections were cut using a microtome
(Leica MR 2145); they were then dewaxed and rehydrated
through a graded ethanol series using routine protocols.
Sections were then washed with distilled water and phos-
phate buﬀered saline (PBS) for 10 minutes and then treated
with 2% trypsin (Sigma chemical Co., St. Lois, Mo, USA)
in 50mM Tris buﬀer (pH 7.5), at 37◦C, for 15 minutes.
Sections were delineated with a Dako pen (Dako, Glostrup,
Denmark) and incubated in a solution of 3% H2O2 for 15
minutes to inhibit endogenous peroxidase activity. Then,
sections were incubated with primary antibodies directed
against iNOS (1:100 dilution; Abcam, Cambridge, UK)
and eNOS (1:1000 dilution; Abcam, Cambridge, UK) all
for 18h at 4◦C in a humid chamber. Sections were then
incubated with biotinylated secondary antibody and then
withstreptavidinconjugatedtohorseradishperoxidase(both
from Zymed Histostain-plus-Peroxidase-kit, 85-9043, San
Francisco, Calif, USA, prepared according to manufac-
turer’s instructions) for 30min each. Finally, sections were
incubated with diaminobenzidine (DAB) (from DeadEnd
Colorimetric TUNEL system, Promega, Madison, USA,
preparedaccordingtomanufacturer’sinstructions)for5min
to reveal immunolabelling. All dilutions and thorough
washes between stages were performed using PBS. Sections
were counterstained with Mayer’s hematoxylin (ZymedInternational Journal of Cell Biology 3
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Figure 1: Mesangial matrix expansion (a) PAS ×40, grade 0; (b) PAS ×40, grade +1; (c) PAS ×40, grade +2; (d) PAS ×40, grade +3; (e) PAS
×40, grade +4.
Laboratories, USA). After washing with tap water, sections
were dehydrated through a graded ethanol series, cleared
in xylene, and mounted with Entellan (Merck). Negative
control samples were processed as described above except
that primary antibodies were omitted and replaced with
PBS alone. Positive controls were represented by sections
of a neuroblastoma specimen known to be positive for the
markers of interest.
2.6. Evaluation of Immunohistochemical Sections. Immuno-
histochemistry was evaluated semiquantitatively (Olympus
BX-51 and Olympus C-5050 digital camera) using an
additive immunoreactive score reﬂecting signal intensity,
that is 0-negative, 1-weak, 2-intermediate, and 3-strong, and
the number of immunopositive cells, that is, 0-no positive
cells, 1-less than 10% positive cells, 2–10% to 50%, and 3-
greater than 50%. 2 scores were added. Measurement was
performed by two independent researchers blind to the drug
administration groups.
2.7. Statistical Analysis. Data were analyzed by using a com-
mercially available statistics software package (SPSS for
Windows v.10.0, Chicago, USA). Since measurement values
did not display homogeneous distribution, Kruskal-Wallis4 International Journal of Cell Biology
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Figure 2: Control and nicotinamide (NAD), (a) and (b) toluidine blue ×40; doxorubicin (DXR); (c) toluidine blue ×40; (d) toluidine blue
×100; (e) toluidine blue ×40; DXR+NAD; (f) toluidine blue ×40.
variance analysis test has been used to evaluate the meaning
of the diﬀerence among the groups. The variance analysis
results which were found meaningful were cross-checked
with Mann-Whitney U-test. Results were presented as mean
± S.E.M. P values <0.05 were regarded as statistically signiﬁ-
cant.
3. Results
3.1. CAT, GPx, and GSH Analysis of Kidney Tissue. The
biochemical results of renal tissue are illustrated in Table 1.
The renal CAT, GPx, and GSH activities were signiﬁcantly
lower in DXR group then the other groups (P<0.001). The
levelsofPoinrenaltissueweresigniﬁcantlyincreasedinDXR
group when compared with other groups (P<0.001).
3.2. Eﬀect of NAD in DXR-Induced Toxicity by Light Micro-
scopic Evaluation. There was no abnormal ﬁndings for the
kidney of both control and NAD groups in the light micro-
scopic examination (Figures 2(a) and 2(b)). Degenerative
changes were observed in the renal glomeruli and tubules
of only DXR group. The urinary spaces and capillaries were
dilated, and the ﬂat epithelial cells of the parietal layer of
Bowman’s membrane could be discerned mostly as cuboidalInternational Journal of Cell Biology 5
Table 1: The activities of catalase (CAT), glutathione peroxidase (GPx), glutathione (GSH), and protein oxidation (Po) levels in renal tissue
of control (n = 6), NAD (n = 8), DXR (n = 8), and DXR plus NAD groups (n = 8). ∗P = 0.001; control versus NAD, DXR, and N+D,
∗∗P = 0.105; control versus N+D.
Markers
Groups GSH (μmoL/mg protein) GPx (μmoL/μg) CAT (μmoL/μg) Protein oxidation (nmoL/μg)
Control 5.32 ± 1.39 1.73 ± 0.38 9.16 ± 4.16 0.35 ± 0.04
NAD 4.85 ± 1.15∗ 0.60 ± 0.11∗ 4.61 ± 0.36∗ 0.15 ± 0.02∗
DXR 2.22 ± 1.06∗ 0.41 ± 0.17∗ 3.84 ± 0.99∗ 4.32 ± 0.20∗
DXR+NAD 4.90 ± 0.9∗∗ 1.48 ± 0.15∗ 20.01 ± 7.40∗ 0.68 ± 0.11∗
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Figure 3: Mesangial matrix expansion % tissue in the kidney
glomeruli.
or round in shape. In the proximal tubules, vacuolization
was observed in the endothelial cell cytoplasm, for the most
part, degenerated, and microvillus is lost (Figures 2(c), 2(d),
and 2(e)). Treatment with NAD resulted in almost normal
tubules and glomeruli in the light microscopic examination
(Figure 2(f)). The graded histological changes (Mesangial
matrix expansion) are summarized in Figure 3.
3.3. Ultrastructural Changes of Kidney Cells. Structure of
kidneys in control and NAD groups was evaluated in the
electron microscopy (Figures 4(a) and 4(b)). Increased
mesangialmatrix(Figure 4(c)),thickening,anduntidinessof
glomerular capillary basement membranes were determined
in DXR groups (Figure 4(d)). In the glomerular area, the
cellular integrity of podocytes was compromised, and the
cytoplasmic foot processes had been withdrawn and adhered
toeachother(Figure 4(e)).Degenerativechangeswerefound
in the proximal tubules, and spaces were observed in the
cytoplasm,formingwide,vacantregionsbetweenthenuclear
and basal membranes (Figure 4(f)). In DXR+NAD group,
the cellular structure was better preserved when compared
with DXR group, and the structure of tubules was better
preserved when compared with DXR group. Treatment with
DXR+NADresultedinalmostnormaltubules(Figure 4(g)).
3.4. Expression of Inducible and Endothelial Nitric Oxide
Synthase. iNOS and eNOS immunoreactivities were investi-
gated in the sections. Immunohistochemical analyses dem-
onstrate that iNOS (Figure 5(a))a n de N O S( Figure 6(a))
expression was weak in the control group. After DXR
application,bothiNOS(Figure 5(c))andeNOS(Figure 6(c))
immunoreactivities were increased signiﬁcantly in kidney
tissue. In DXR group, kidney sections showed increased
expression of eNOS in interstitial, endothelial, and mac-
ula densa cells, while decreased expression was obtained
in NAD-treated group (Figures 5(b)–6(b)). Immunohisto-
c h e m i c a lr e a c t i o nw a ss t r o n gi nD X Ra n dw e a ki nN A D
group when compared with control group. Combined
application of DXR and NAD showed intermediate iNOS
(Figure 5(d))a n de N O S( Figure 6(d)) expression in kidney
tissue. In summary, iNOS and eNOS immunohistochemical
analysis demonstrated markedly decreased eﬀect of NAD in
DXR-induced kidney toxicity. DXR-induced toxicity showed
anincreasediNOSandeNOSimmunohistochemicalanalysis
results, and this eﬀect was markedly decreased with NAD
treatment.
4. Conclusion
In the present study, our ﬁrst goal was to demonstrate the
intense correlation between DXR-related iNOS and eNOS
immunoreactivity in tissue damage and the protective eﬀects
of NAD with decreased iNOS and eNOS immunoreactivity.
Moreover, we showed DXR-induced tissue injury in the
kidney, and the damage was demonstrated by microscopic
and biochemical evaluations.
Anticancer therapy usually demolishes the physiological
homoeostasis and aﬀects multiple organs during treatment
process. Eﬀective anticancer therapy with anthracyclines is
limited because of its toxicity to various organs including
kidneys [19, 20]. The toxicity has been attributed to radical
formation and oxidant injury. Nephrotoxic action of DXR
is also considered to be via drug-induced free radical
generation [21, 22]. The formation of free radicals as well
as an increase in response to DXR treatment has already
been documented. The disturbance in oxidant-antioxidant
systems results in tissue injury that is demonstrated with
protein oxidation in tissue and protein oxidation in renal
tissue, is recognized as one of the possible biochemical
mechanisms of DXR-induced nephrotoxicity [3], and we
have found that DXR treatment raised Po (protein oxidation
product) in rat kidney.
NOS may be responsible for the reductive activation of
DXRtoitsfreeradicalsemiquinoneformandthesubsequent
oxygen radical-mediated cellular damage [23]. Our results
showed the elevated immunoactivation of both iNOS and
eNOS after DXR treatment. In DXR group, ultrastructural
changes such as cellular damage and glomerular and tubular
degeneration were determined.6 International Journal of Cell Biology
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Figure 4: (a) and (b) Control ×3000 and nicotinamide (NAD) ×10K; doxorubicin (DXR), (c) ×3000, (d) ×10k, (e) ×30K, (f) ×5000,
DXR+NAD, (g) ×500.
GSH plays an important role in the detoxiﬁcation of
xenobiotic compounds and in the antioxidation of reactive
o x y g e ns p e c i e sa n df r e er a d i c a l s .L o wl e v e l so fG S Hw e r e
observed in oxidative stress. This observation supports our
ﬁnding in which we have observed a decline in GSH
levels with an increase in oxidative stress as evidenced by
increased LPO [24]. A decrease in the activity of CAT was
observed with DXR administration [25]. The above ﬁnding
corroborates with our results where we have observed a
reduction in the CAT activity.
Deman et al. [22] demonstrated reduced glutathione
concentration in the renal cortex supports the idea of free
radical involvement in nephrotoxicity of DXR. In the present
study, we showed reduced glutathione in the renal tissue.
It was shown by Yagmurca et al. [13] that 20mg/kg single
dose of DXR resulted in renal LPO at the 10th day of DXRInternational Journal of Cell Biology 7
(a) (b)
(c) (d)
Figure 5: (a) and (b) iNOS control and nicotinamide (NAD), (c) Doxorubicin (DXR), (d) DXR+NAD.
injection in rats. We also demonstrated that CAT, GSH, and
GPx activities were decreased 10 days after DXR treatment.
Yagmurca et al. demonstrated that glomerular sclerosis was
seen 10 days after DXR injection in rats. Also, it was shown
that there was thickening of capillary basement membrane
in the DXR group. Urinary spaces and capillaries were
dilated, and the ﬂat epithelial cells of the parietal layer of
Bowman’s membrane could be discerned mostly as cuboidal
orroundinshape.Intheproximaltubules,vacuolizationwas
observed in the endothelial cell cytoplasm, for the most part,
degenerated, and microvillus is lost (Figure 2(d)). Studies
carried out by Fajarda et al. [26] and Strenberg et al. [27]
showed that cytoplasmic foot processes of podocytes were
damaged with DXR. Identical results were also found in our
study. Vacuoles were observed in the cytoplasm between the
nuclei and cellular membranes of the tubules.
Another radical formatting mechanism in such an exper-
imental protocol might be NO producing system. The high
production of NO results in peroxynitrite formation via NO
reacting with superoxide anion. Peroxynitrite is a potent and
aggressive cellular oxidant and causes the formation of 3-
nitro-L-tyrosine [28]. iNOS is involved in the inﬂammatory
process. It was also shown in recent years that high NO
production is involved in DXR toxicity [29, 30]. The present
study demonstrated that NO production was increased in
renaltissueofDXR-treatedrats.AscontrolandNADgroups’
area that has been dyed overly, it might also be related to the
inﬂammatory answer of the tissue against DXR.
DXR has widely been used in many countries for
hematological malignancies. However, the toxic eﬀect on
the kidneys and consequently acute renal failure producing
eﬀect of DXR is a limiting factor of its usefulness. Therefore,
novel therapeutic agents with improved eﬃcacy seem to be
considerable for clinical approach. NAD has been shown
to possess anti-inﬂammatory, anticancer, and antioxidant
properties [31]. Previous studies have demonstrated that
NAD exhibits antioxidant properties against oxidant con-
ditions that cause tissue injury and may prevent carbon
tetrachloride-induced liver ﬁbrosis in rat via antioxidant
mechanism [31]. The present study indicated that NAD
treatment caused decreased LPO and protein oxidation in
the kidney tissue after DXR administration. Also, NAD
prevented the histopathological changes occurred due to
DXR toxicity in rat kidney in this study.8 International Journal of Cell Biology
(a) (b)
(c) (d)
Figure 6: (a) and (b) eNOS control and nicotinamide (NAD), (c) doxorubicin (DXR), (d) DXR+NAD.
In conclusion, the present study demonstrates that
20mg/kg single injection of DXR to the Wistar-Albino rats
caused renal injury including glomerular and tubular lesion
10 days after the DXR injection. Furthermore, this study
revealed that pretreatment with NAD protected renal tissues
against DXR-induced nephrotoxicity. Preventive eﬀects of
NAD on these renal lesions may be via its antioxidant and
anti-inﬂammatory action. Although the exact mechanisms
remain to be clariﬁed, NAD could be an eﬀective course of
therapy to enhance therapeutic eﬃcacy and to lessen DXR
toxicity in clinical chemotherapy.
Abbreviations
NAD: Nicotinamide
DXR: Doxorubicin
GSH: Glutathione
CAT: Catalase
GPx: Glutathione peroxidase
Po: Protein oxidation
iNOS: Inducible nitric oxide synthase
eNOS: Endothelial nitric oxide synthase
PAS: Periodic acid-Schiﬀ
LPO: Lipid peroxidation.
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